Test drug fb-PMT in recurrent brain cancer patients
Part of Cancer clinical trials.
This Phase 1 study tests how safe and tolerable fb-PMT is for people with glioblastoma that has come back. It also helps doctors learn the best way to give it and what side effects to watch for.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have glioblastoma in the brain that has returned once (first or second recurrence) and was confirmed by pathology (biopsy/surgery tissue).
- Your brain scans (MRI with and without contrast) must be done within 5 days before starting the study drug.
- You must have finished standard treatments (surgery/biopsy and radiation) and recovered, and your disease must be confirmed as “progressive” for certain prior radiation types.
- You need to be able to take daily refrigerated medicine, give daily skin shots on schedule, and keep a daily treatment diary.
- Your overall condition must be good (Karnofsky Performance Status 70 or higher), and you must have enough blood and organ function on screening labs.
- Women who can become pregnant must agree to ongoing pregnancy tests and reliable birth control during the study and for 2 months after the last dose; men must agree to use birth control and not donate sperm for 2 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests a new brain-tumor treatment in people with recurrent (coming back) high-grade glioma (brain cancer). The study uses injected medicine along with an implanted tumor device and aims to find whether the treatment is safe and can shrink or control tumors.
This Phase 2 study tests ERC1671 together with four other medicines to treat recurrent or worsening glioblastoma (a WHO grade IV brain cancer). It aims to slow tumor growth and improve outcomes after the tumor comes back.
This trial tests an experimental drug, BMS-986504, for people with recurrent glioblastoma (a type of brain cancer). The drug targets a specific genetic change in the tumor. It aims to see if the drug can help shrink or slow the tumor.
This trial tests a new drug called BL-B01D1 for people whose glioblastoma has come back after standard treatment. The goal is to see if the drug can help control the tumor.
This trial tests an investigational drug called pumitamig (also known as BNT327) in people whose glioblastoma has come back after standard treatment with radiation and temozolomide. The goal is to see if the drug is safe and whether it can help slow or stop tumor growth.
This study is testing whether special MRI scans and blood tests can help tell the difference between true tumor growth (progression) and a treatment-related reaction called 'pseudoprogression' in people with glioblastoma. The goal is to make treatment decisions more accurate.
Hear when a new Glioma, Malignant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.